OSTEOGROW, an EU-funded collaborative research project, is investigating a new bone regeneration therapy based on autologous blood + BMP-6 for use in applications requiring partial bone replacement, without the need for secondary interventions.Â
RTI Surgical received regulatory clearance for nanOss® Bioactive bone void filler in Australia, as well as CE Mark for nanOss Bioactive Loaded and nanOss Bioactive 3D in Europe.Â
Bioventus launched the EXOGEN® Ultrasound Bone Healing System in Saudi Arabia for distribution by Zimmo Trading Company, which also markets DUROLANE® single-injection hyaluronic acid osteoarthritis treatment.
Histogenics seeks to raise ~US $30.0MM in a private placement. Net proceeds will support development of NeoCart® cartilage repair therapy, including completion of an ongoing Phase III clinical trial.